BALTIMORE, MD, March 20, 2015 – BD Life Sciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it obtained CE Mark for the BD MAX™ CT/GC/TV and CT/GC assays, new additions to the BD Reproductive and Sexually Transmitted Infections Portfolio. The BD MAX™ CT/GC/TV and CT/GC assays will provide customers the ability to detect for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV) from a single specimen in just one run.
CT, GC and TV are among the most prevalent sexually transmitted infections (STIs). The World Health Organization estimates that globally 105.7 million new cases of infection due to Chlamydia trachomatis, 106.1 million new cases of infection due to Neisseria gonorrhoeae and 27.4 million new cases of Trichomonas vaginalis occur each year.1 These infections can have serious consequences if left unaddressed, such as pelvic inflammatory disease, ectopic pregnancy, infertility, pre-term or low birth-weight babies and increased risk of STI transmission or infection (including HIV) in males and females.
The BD MAX™ CT/GC/TV and CT/GC assays represent yet another molecular diagnostics innovation for BD Life Sciences – Diagnostic Systems. With these assays, customers will be able to detect these common and addressable STIs in a single specimen and run. Collection options are flexible, allowing for male or female urines, self-collected vaginal swabs and clinician collected endocervical swabs. Once samples are loaded onto the BD MAX™ System, results will be ready in less than three hours, and all reagents are ready-to-use, room temperature storage.
"We're pleased to be able to offer customers the convenience and performance of our BD MAX™ CT/GC/TV and CT/GC assays along with the capabilities of our easy-to-use, fully automated BD MAX™ platform,” said Doug White, Vice President and General Manager, Molecular Diagnostics and Women’s Health, BD Life Sciences – Diagnostic Systems. “We are dedicated to expanding the BD MAX™ portfolio with clinically relevant assays that help enable our customers to improve clinical outcomes while providing enhanced workflow and efficiency in the clinical laboratory.”
The BD MAX™ System offers an efficient path to improved clinical outcomes by combining and automating real-time PCR extraction, amplification and detection and into a single platform capable of running both FDA-cleared and open-system assays. Such flexibility and standardization allow you to address a wide breadth of testing needs. The BD MAX™ System is part of a BD Life Sciences – Diagnostic Systems portfolio of molecular solutions. For more information on BD Molecular Diagnostics, please visit: http://moleculardiagnostics.bd.com.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.